Amylyx Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Amylyx PharmaceuticalsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -17.6% zurückgegangen, während in der Branche Pharmaceuticals die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 71% pro Jahr.

Wichtige Informationen

-17.6%

Wachstumsrate der Gewinne

34.4%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	6.0%
Wachstumsrate der Einnahmen	71.0%
Eigenkapitalrendite	-132.2%
Netto-Marge	-132.1%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Aufschlüsselung der Einnahmen und Ausgaben

Wie Amylyx Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:AMLX Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Sep 24	196	-259	149
30 Jun 24	299	-166	180
31 Mar 24	398	-71	202
31 Dec 23	381	49	188
30 Sep 23	294	2	177
30 Jun 23	192	-73	158
31 Mar 23	94	-149	145
31 Dec 22	22	-198	127
30 Sep 22	0	-184	101
30 Jun 22	0	-153	82
31 Mar 22	0	-121	59
31 Dec 21	0	-88	39
30 Sep 21	1	-68	28
31 Dec 20	1	-42	15
31 Dec 19	1	-14	3

Qualität der Erträge: AMLX ist derzeit unrentabel.

Wachsende Gewinnspanne: AMLX ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: AMLX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 17.6% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von AMLX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: AMLX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (54.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: AMLX hat eine negative Eigenkapitalrendite (-132.24%), da es derzeit unrentabel ist.

Amylyx Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings released: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)

Amylyx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Amylyx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Amylyx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Consensus EPS estimates fall by 22%

Co-Founder exercised options to buy US$427k worth of stock.

Third quarter 2024 earnings released: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 25% to US$5.33

Amylyx Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2 Helios Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals, Inc. to Host Virtual Webcast to Discuss Topline Results from Phase 2 Helios Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Co-Founder recently sold US$59k worth of stock

Co-Founder exercised options to buy US$99k worth of stock.

Chief Financial Officer recently bought US$101k worth of stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Independent Chairman of the Board recently bought US$220k worth of stock

Consensus EPS estimates fall by 30%

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of Amx0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’S Disease Pathology and Neurodegeneration

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Amylyx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Index

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

New minor risk - Profitability

Investor sentiment improves as stock rises 15%

Amylyx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Investor sentiment deteriorates as stock falls 20%

Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Consensus revenue estimates fall by 45%

Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market

New major risk - Revenue and earnings growth

Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors

Investor sentiment deteriorates as stock falls 83%

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Rosen Law Firm Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Consensus revenue estimates fall by 19%

An ALS Drug Fails Again

Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Investor sentiment improves as stock rises 28%

Consensus EPS estimates fall by 54%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Amylyx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy (Psp)

Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer

Price target decreased by 17% to US$39.40

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

New minor risk - Share price stability

Amylyx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium

Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing Centaur to Historical Clinical Trial Control

Amylyx Pharmaceuticals Provides Update on Acces Compassionnel for AMX0035 in France

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Amylyx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Quebec for the Public Reimbursement of Albriza

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Ontario for Public Reimbursement of ALBRIOZA Through Ontario Drug Benefit Program

Amylyx Pharmaceuticals, Inc. Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Amylyx Pharmaceuticals, Inc. Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

Insider notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Forecast breakeven date moved forward to 2023